“…With the development of different kinds of treatment technologies, the 5-year survival rate of early-stage colon cancer patients has increased up to 90%, however, many urgent problems remain to be solved: for example, the median survival time of colon cancer patients with metastasis is less than 2 years, and 5-year overall survival rate is only 50–65%. Early screening and diagnosis for colon cancer mainly depend on electronic colorectal mirror surgery and pathology, which is expensive and has poor prognosis ( Kiriyama et al, 2012 ; Chiba et al, 2014 ; Missiaglia et al, 2014 ; Fakih, 2015 ; Miller et al, 2016 ; Sewda et al, 2016 ; Marmol et al, 2017 ; White et al, 2017 ; Zhao et al, 2017 ; Hu et al, 2020 ; Mo et al, 2020 ; Hu et al, 2021a ; Hu et al, 2021b ). As a result, molecular biomarkers are vital for verifying the mechanism that promotes colon cancer development and improving early screening, diagnosis, and treatment for colon cancer.…”